Compare
Prestige Consumer Healthcare Inc. vs Madrigal Pharmaceuticals, Inc. vs Ionis Pharmaceuticals Inc vs Harmony Biosciences Holdings, Inc.
| Latest fiscal year | Prestige Consumer Healthcare Inc. PBH | Madrigal Pharmaceuticals, Inc. MDGL | Ionis Pharmaceuticals Inc IONS | Harmony Biosciences Holdings, Inc. HRMY |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.09B | $958.40M | $943.71M | $868.45M |
| Revenue growth (YoY) | -4.3% | +432.1% | +33.8% | +21.5% |
| Gross margin | 54.7% | n/a | n/a | 77.2% |
| Operating margin | 28.4% | -31.3% | -40.4% | 24.0% |
| Net margin | 17.5% | -30.1% | -40.4% | 18.3% |
| Net income | $190.30M | -$288.28M | -$381.39M | $158.69M |
| EPS (Diluted) | $3.91 | -$12.85 | -$2.38 | $2.71 |
| Operating cash flow | $257.63M | -$189.55M | -$268.58M | $348.20M |
| Free cash flow | $246.45M | -$190.02M | -$320.03M | $347.89M |
| Cash & equivalents | $63.87M | $198.69M | $372.26M | $752.50M |
| Total assets | $3.49B | $1.26B | $3.52B | $1.27B |
| Total liabilities | $1.61B | $656.90M | $3.03B | $401.41M |
| Shareholders' equity | $1.89B | $602.69M | $489.09M | $870.22M |
| Return on year-end equity | 10.1% | -47.8% | -78.0% | 18.2% |
| Shares outstanding | n/a | 22.84M | 163.30M | 57.73M |
Revenue, most recent five fiscal years
| Fiscal year | Prestige Consumer Healthcare Inc. | Madrigal Pharmaceuticals, Inc. | Ionis Pharmaceuticals Inc | Harmony Biosciences Holdings, Inc. |
|---|---|---|---|---|
| Latest | $1.09B Ended 2026-03-31 | $958.40M Ended 2025-12-31 | $943.71M Ended 2025-12-31 | $868.45M Ended 2025-12-31 |
| 1 year earlier | $1.14B Ended 2025-03-31 | $180.13M Ended 2024-12-31 | $705.14M Ended 2024-12-31 | $714.73M Ended 2024-12-31 |
| 2 years earlier | $1.13B Ended 2024-03-31 | $0 Ended 2023-12-31 | $787.65M Ended 2023-12-31 | $582.02M Ended 2023-12-31 |
| 3 years earlier | $1.13B Ended 2023-03-31 | $0 Ended 2022-12-31 | $587.37M Ended 2022-12-31 | $437.86M Ended 2022-12-31 |
| 4 years earlier | $1.09B Ended 2022-03-31 | $0 Ended 2021-12-31 | $810.46M Ended 2021-12-31 | $305.44M Ended 2021-12-31 |